Repository logo
 

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.

dc.contributor.authorShey, Muki Shehu.
dc.contributor.authorKongnyuy, Eugene J.
dc.contributor.authorAlobwede, Samuel M.
dc.contributor.authorWiysonge, Charles Shey.
dc.date.accessioned2013-12-09T07:21:32Z
dc.date.available2013-12-09T07:21:32Z
dc.date.created2013
dc.date.issued2013
dc.description.abstractThe primary objective of this review was to evaluate the antiviral efficacy of co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and tolerability of the triple drug combination. We identified 15 potentially eligible studies, four of which met our inclusion criteria. Our findings indicate that co-formulated abacavirlamivudine-zidovudine remains a viable option for initiating antiretroviral therapy, especially in HIV-infected patients with pre-existing hyperlipidaemia and those who do not tolerate ritonavir.en
dc.identifier.citationShey, M.S., Kongnyuy, E.J., Alobwede, S.M., Wiysonge, C.S. 2013. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS. Cochrane Database of Systematic Reviews (3) Art. No.: CD005481.
dc.identifier.issn1469-493X
dc.identifier.urihttp://dx.doi.org/10.1002/14651858.CD005481.pub3.en
dc.identifier.urihttp://hdl.handle.net/10413/10180
dc.language.isoenen
dc.publisherThe Cochrane Collaboration.en
dc.subjectHIV infections--Drug therapy.en
dc.subjectAntiretroviral agents.en
dc.subject.otherCombination antiretroviral therapy.en
dc.subject.otherTriple drug combination.en
dc.titleCo-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.en
dc.typePeer reviewed journal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Shey_Muki_S_2013.pdf
Size:
248 KB
Format:
Adobe Portable Document Format
Description:
Review

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.64 KB
Format:
Item-specific license agreed upon to submission
Description: